This #SMAAwarenessMonth, we recognize and celebrate the people living with spinal muscular atrophy (SMA), whose experiences continue to deepen understanding of the disease and inspire our ongoing commitment to driving innovation for the SMA community. Hear from Sory on why continued awareness matters and her hopes for a more inclusive future.
About us
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we have world-class manufacturing facilities in North Carolina and Solothurn, Switzerland. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Community Guidelines: https://www.biogen.com/community-guidelines.html Follow us on social media – LinkedIn, Instagram, Facebook, X, and YouTube.
- Website
-
http://www.biogen.com
External link for Biogen
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
Locations
-
Primary
Get directions
225 Binney Street
Cambridge, MA 02142, US
-
Get directions
Landis & Gyr-Strasse 3
Zug, CH 6300, CH
-
Get directions
P.O. Box 14627
5000 Davis Drive
Research Triangle Park, NC 27709, US
Employees at Biogen
Updates
-
Today, we announced the completion of the acquisition of RayThera Inc. This acquisition marks another step in growing Biogen’s immunology portfolio, adding multiple potential assets for immune-mediated diseases, including a lead program in Phase 1 development. Read more about this news: http://spr.ly/6041B1DllD
-
While advances in spinal muscular atrophy (SMA) have helped change what’s possible for people living with SMA, there is still more to be done. In recognition of the 30th Anniversary of SMA Awareness Month, hear from our team about what motivates them to keep advancing research and pursuing better outcomes for the SMA community.
-
We’re attending #GlomConHawaii to share more about our approach to C3G and primary IC-MPGN. Stop by booth #25 to learn how Biogen is working to transform care in complement-driven and immune-mediated kidney diseases.
-
We were proud to sponsor SPARK 2026, hosted by The IgA Nephropathy Foundation to bring together patients, caregivers and industry experts. At Biogen, we recognize that strong partnerships with advocacy organizations and patient communities are crucial to advancing progress. Through our ongoing research, including exploring CD38-targeted approaches, we hope to improve outcomes that can ultimately help reshape the future of care for people living with IgA nephropathy.
-
-
We’re pleased to welcome Michael Parini to Biogen as Chief Legal Officer. Michael brings more than 20 years of senior legal and strategic leadership experience across the healthcare industry and will play a critical role in helping to execute our strategy and build the future of Biogen. Welcome to #TeamBiogen, Michael!
-
For many kidney transplant recipients, antibody-mediated rejection (AMR) remains a serious and difficult challenge. Our Senior Clinical Development Lead for Transplant, Gordon I., shares how Biogen is working to bring innovation to this community.
-
STARTING SOON: Join our Q2 2026 earnings call webcast at 8:30AM ET here: http://spr.ly/6049BEIIjb
-
-
Today, we reported our Q2 results, demonstrating progress toward our goal of sustainable revenue growth. We are bringing our vision for the New Biogen to life, with a growing commercial business, a pipeline of anticipated readouts, and an expanding early-stage pipeline. Read more: https://lnkd.in/gC2ac6N3 Forward-looking statements: https://lnkd.in/gPk22_2Q
-
As a company driven by breakthrough science and a commitment to improving lives, Biogen is proud to have celebrated America’s 250th anniversary through service. Across the country, #TeamBiogen came together to make a meaningful impact on the communities where we work and live. See how our employees are honoring this historic milestone by giving back. Thanks to the Boston Symphony Orchestra, Museum of Fine Arts, Boston, Red Sox Foundation and to Sail Boston for allowing us to join in welcoming our colleagues to these special celebrations.